Pentacel 29 Unit (Poliovirus Type 1 Mahoney (Inactivated) SUSPENSION) 29 UNIT

Pentacel 29 Unit is a vaccine suspension used to protect against certain infectious diseases. This intramuscular injection contains inactivated poliovirus type 1 Mahoney and is manufactured by Sanofi Pasteur Limited in Canada.

Strength

29 UNIT

Manufacturer / TM Owner

SANOFI PASTEUR LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pentacel 29 Unit is primarily used for the prevention of poliomyelitis, a serious viral infection caused by the poliovirus. This vaccine is designed to help the body build immunity against the disease, reducing the risk of infection. It is typically administered as part of a vaccination schedule to ensure long-term protection.

Side Effects

Common effects of Pentacel 29 Unit may include mild redness, swelling, or tenderness at the injection site. Some individuals might experience mild fever, fatigue, or general discomfort following vaccination. These effects are usually temporary and resolve on their own.

Precautions & Warnings

Pentacel 29 Unit should be handled with care and stored according to the manufacturer's guidelines. It is important to inform healthcare providers about any allergies or medical conditions before receiving this vaccine. Always follow the advice of a healthcare professional regarding vaccination.

Avoid Interactions

Pentacel 29 Unit may interact with other medications or vaccines. It is advisable to discuss any current medications or recent vaccinations with a healthcare provider before receiving this vaccine. Avoid taking any other medications without consulting a healthcare professional.

Frequently Asked Questions

Pentacel 29 Unit is used to prevent poliomyelitis, a viral infection caused by the poliovirus.

Pentacel 29 Unit is administered as an intramuscular injection.

Common effects may include mild redness, swelling, or tenderness at the injection site, as well as mild fever or fatigue.

Individuals with a history of severe allergic reactions to any component of the vaccine or those with certain medical conditions should consult a healthcare provider before receiving Pentacel 29 Unit.

It is important to discuss any current medications with a healthcare provider before receiving Pentacel 29 Unit to avoid potential interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.